Biocept TRK Assay

Biocept said it has launched a new assay for detection of TRK proteins in circulating tumor cells, intended to help inform physicians of patients' NTRK fusion status, an actionable biomarker that can be used to qualify patients for treatment with TRK inhibitor therapies.

The launch brings the company's CLIA lab test menu to 20 assays, including a variety of other single-gene tests analyzed in either circulating cell-free DNA or CTCs, and a next-gen sequencing panel test for lung cancer biomarkers.